Active Switch From a Single Dose of Bimekizumab to Risankizumab in Psoriasis: A Pilot Study

Tomomitsu Miyagaki is an Associate Editor and Takafumi Kadono is an Editor-in-Chief of the Journal of Dermatology. They are coauthors of the current article. To minimize bias, they were excluded from all editorial decision-making related to the acceptance of this article for publication. There are no other conflicts of interest to be declared. Table S1. Demographics of patients at baseline. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.